{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:26:38Z","timestamp":1771039598943,"version":"3.50.1"},"reference-count":115,"publisher":"Oxford University Press (OUP)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.2146\/ajhp150373","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T10:08:08Z","timestamp":1477044488000},"page":"1729-1744","source":"Crossref","is-referenced-by-count":14,"title":["Management of neuroendocrine tumors"],"prefix":"10.1093","volume":"73","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Lyndon B. Johnson General Hospital, Harris Health System, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041103111539900_b1-0731729","unstructured":"Khan A , SteinJ. Steve Jobs, dead at 56, had a rare form of pancreatic cancer (October06, 2011). http:\/\/articles.latimes.com\/2011\/oct\/06\/news\/la-heb-steve-jobs-died-pancreatic-cancer-20111005 (accessed 2015 Feb 26)."},{"key":"key\n\t\t\t\t2019041103111539900_b2-0731729","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel American Joint Committee on Cancer staging classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b3-0731729","first-page":"290","volume-title":"AJCC cancer staging handbook: from the AJCC cancer staging manual","year":"2009","edition":"7th"},{"key":"key\n\t\t\t\t2019041103111539900_b4-0731729","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/annonc\/mdq022","article-title":"Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the national Cancer Registry of Spain (RGETNE)","volume":"21","author":"Garcia-Carbonero","year":"2010","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b5-0731729","unstructured":"National Cancer Institute. SEER (surveillance, Epidemiology and End Results) statistics. http:\/\/seer.cancer.gov (accessed 2015 Feb 27)."},{"key":"key\n\t\t\t\t2019041103111539900_b6-0731729","first-page":"426","article-title":"Karzinoide tumoren des d\u00fcnndarms","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Z Pathol"},{"key":"key\n\t\t\t\t2019041103111539900_b7-0731729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0011-3840(84)90033-9","article-title":"Tumors of the neuroendocrine system (APUD cell tumors\u2014Apudomas)","volume":"21","author":"Welbourn","year":"1984","journal-title":"Curr Probl Surg"},{"key":"key\n\t\t\t\t2019041103111539900_b8-0731729","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"key":"key\n\t\t\t\t2019041103111539900_b9-0731729","first-page":"137","article-title":"Endocrine tumours of the colon and rectum","volume-title":"World Health Organization classification of tumours, pathology and genetics of tumours of the digestive system","author":"Capella","year":"2000"},{"key":"key\n\t\t\t\t2019041103111539900_b10-0731729","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel American Joint Committee on Cancer staging classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b11-0731729","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: neuroendocrine tumors. V.1.2015. Available from www.nccn.org (accessed 2015 Mar 30)."},{"key":"key\n\t\t\t\t2019041103111539900_b12-0731729","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"key":"key\n\t\t\t\t2019041103111539900_b13-0731729","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1245\/s10434-007-9566-6","article-title":"Population-based study of islet cell carcinoma","volume":"14","author":"Yao","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b14-0731729","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2019041103111539900_b15-0731729","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.gassur.2005.08.023","article-title":"Surgery for primary pancreatic neuroendocrine tumors","volume":"10","author":"Norton","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"key\n\t\t\t\t2019041103111539900_b16-0731729","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"key\n\t\t\t\t2019041103111539900_b17-0731729","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/107327480801500406","article-title":"Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?","volume":"15","author":"Hodul","year":"2008","journal-title":"Cancer Control"},{"key":"key\n\t\t\t\t2019041103111539900_b18-0731729","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1093\/annonc\/mdr614","article-title":"A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors","volume":"23","author":"Strosberg","year":"2012","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b19-0731729","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jvir.2013.02.030","article-title":"Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases","volume":"24","author":"Hur","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"key\n\t\t\t\t2019041103111539900_b20-0731729","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","article-title":"Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases","volume":"113","author":"King","year":"2008","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b21-0731729","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1477-2574.2012.00528.x","article-title":"Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection","volume":"15","author":"Taner","year":"2013","journal-title":"HPB (Oxford)"},{"key":"key\n\t\t\t\t2019041103111539900_b22-0731729","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b23-0731729","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1245\/s10434-014-3523-y","article-title":"Liver transplantation for unresectable neuroendocrine tumor liver metastases","volume":"21","author":"Rossi","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b24-0731729","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3348\/kjr.2009.10.5.425","article-title":"The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"10","author":"Shin","year":"2009","journal-title":"Korean J Radiol"},{"key":"key\n\t\t\t\t2019041103111539900_b25-0731729","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00270-004-4082-6","article-title":"Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques","volume":"28","author":"Atwell","year":"2005","journal-title":"Cardiovasc Intervent Radiol"},{"key":"key\n\t\t\t\t2019041103111539900_b26-0731729","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1051-0443(99)70055-2","article-title":"Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms","volume":"10","author":"Brown","year":"1999","journal-title":"J Vasc Interv Radiol"},{"key":"key\n\t\t\t\t2019041103111539900_b27-0731729","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00268-001-0013-8","article-title":"Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization","volume":"25","author":"Proye","year":"2001","journal-title":"World J Surg"},{"key":"key\n\t\t\t\t2019041103111539900_b28-0731729","first-page":"1029","article-title":"Chimio-embolisation hepatique","volume":"76","author":"Roche","year":"1989","journal-title":"Bull Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b29-0731729","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s10147-012-0445-1","article-title":"Current status of embolic agents for liver tumor embolization","volume":"17","author":"Osuga","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b30-0731729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2011.06.013","article-title":"Chemoembolization agents for cancer treatment","volume":"44","author":"Tam","year":"2011","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t2019041103111539900_b31-0731729","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2006.10.020","article-title":"Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics","volume":"46","author":"Varela","year":"2007","journal-title":"J Hepatol"},{"key":"key\n\t\t\t\t2019041103111539900_b32-0731729","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"key\n\t\t\t\t2019041103111539900_b33-0731729","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/01.RVI.0000228416.21560.7F","article-title":"Pharmacokinetic and safety study of doxorubicin eluting beads in a porcine model of hepatic arterial embolization","volume":"17","author":"Lewis","year":"2006","journal-title":"J Vasc Interv Radiol"},{"key":"key\n\t\t\t\t2019041103111539900_b34-0731729","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1186\/s12885-015-1480-x","article-title":"Conventional transarterial chemoembolization versus drug-eluting transarterial chemoembolization for the treatment of hepatocellular carcinoma","volume":"15","author":"Kloeckner","year":"2015","journal-title":"BMC Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b35-0731729","doi-asserted-by":"crossref","first-page":"W706","DOI":"10.2214\/AJR.13.12308","article-title":"Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC","volume":"203","author":"Prajapati","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"key\n\t\t\t\t2019041103111539900_b36-0731729","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/jcpt.12230","article-title":"Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma","volume":"40","author":"Vadot","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"key\n\t\t\t\t2019041103111539900_b37-0731729","doi-asserted-by":"crossref","first-page":"e102686","DOI":"10.1371\/journal.pone.0102686","article-title":"Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis","volume":"9","author":"Han","year":"2014","journal-title":"PLoS ONE"},{"key":"key\n\t\t\t\t2019041103111539900_b38-0731729","volume-title":"LC Bead and LC BeadM1 embolic agent instructions for use","year":"2015"},{"key":"key\n\t\t\t\t2019041103111539900_b39-0731729","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b40-0731729","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogues for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b41-0731729","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1385\/MO:20:1:59","article-title":"Expression of somatostatin receptor subtype 1\u20135 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumor","volume":"20","author":"Fjallskog","year":"2003","journal-title":"Med Oncol"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041103111539900_b42-0731729","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000080743","article-title":"Future aspects of somatostatin-receptor mediated therapy","volume":"80","author":"Oberg","year":"2004","journal-title":"Neuroendocrinology"},{"key":"key\n\t\t\t\t2019041103111539900_b43-0731729","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"key\n\t\t\t\t2019041103111539900_b44-0731729","first-page":"vii","article-title":"Neuroendocrine gastroentero-pancreatic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b45-0731729","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"key\n\t\t\t\t2019041103111539900_b46-0731729","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/annonc\/12.suppl_2.S105","article-title":"The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard cutaneous octreotide therapy","volume":"12","author":"Dogliotti","year":"2001","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b47-0731729","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103111539900_b48-0731729","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0026-0495(96)90070-0","article-title":"Molecular and functional properties of somatostatin receptor subtypes","volume":"45","author":"Liapakis","year":"1996","journal-title":"Metabolism"},{"key":"key\n\t\t\t\t2019041103111539900_b49-0731729","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nrd1255","article-title":"Opportunities in somatostatin research: biological, chemical and therapeutic aspects","volume":"2","author":"Weckbecker","year":"2003","journal-title":"Nature Rev Drug Discov"},{"key":"key\n\t\t\t\t2019041103111539900_b50-0731729","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"issue":"15 suppl","key":"key\n\t\t\t\t2019041103111539900_b51-0731729","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1200\/jco.2012.30.15_suppl.4119","article-title":"Pazonet: results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs (GETNE)-NCT01280201","volume":"30","author":"Grande Pulido","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b52-0731729","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041103111539900_b53-0731729","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"key\n\t\t\t\t2019041103111539900_b54-0731729","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041103111539900_b55-0731729","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique anti-secretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041103111539900_b56-0731729","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b57-0731729","unstructured":"ClinicalTrials.gov. Dose escalation study of pasireotide (SOM230) in patients with advanced neuroendocrine tumors (NETs). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01364415 (accessed 2015 Jun 1)."},{"issue":"suppl","key":"key\n\t\t\t\t2019041103111539900_b58-0731729","article-title":"A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs","volume":"31","author":"Wolin","year":"2013","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b59-0731729","first-page":"81","article-title":"Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"key\n\t\t\t\t2019041103111539900_b60-0731729","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.mpa.0000186249.89081.0d","article-title":"Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors","volume":"31","author":"Woltering","year":"2005","journal-title":"Pancreas"},{"key":"key\n\t\t\t\t2019041103111539900_b61-0731729","unstructured":"Institute for Safe Medication Practices. ISMP\u2019s list of products with drug name suffixes. www.ismp.org\/tools\/drugnamesuffixes.pdf (accessed 2015 May 28)."},{"key":"key\n\t\t\t\t2019041103111539900_b62-0731729","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041103111539900_b63-0731729","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bpg.2005.04.001","article-title":"Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy","volume":"19","author":"Teunissen","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"key\n\t\t\t\t2019041103111539900_b64-0731729","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings","volume":"32","author":"De Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"key\n\t\t\t\t2019041103111539900_b65-0731729","first-page":"1556","article-title":"Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors","volume":"44","author":"Bushnell","year":"2003","journal-title":"J Nucl Med"},{"key":"key\n\t\t\t\t2019041103111539900_b66-0731729","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.semnuclmed.2009.10.004","article-title":"Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Kwekkeboom","year":"2010","journal-title":"Semin Nucl Med"},{"key":"key\n\t\t\t\t2019041103111539900_b67-0731729","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/eje.1.01901","article-title":"Octreotide in insulinoma patients: efficacy of hypoglycemia, relationships with Octreoscan scintography and immunostaining with anti-sst 2A and anti-sst5 antibodies","volume":"152","author":"Vezzosi","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041103111539900_b68-0731729","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"key\n\t\t\t\t2019041103111539900_b69-0731729","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000403785","article-title":"The role of chemotherapy in well-differentiated gastroenteropancreatic neuroendocrine tumors","volume":"44","author":"Strosberg","year":"2015","journal-title":"Front Horm Res"},{"key":"key\n\t\t\t\t2019041103111539900_b70-0731729","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.2004.09.075","article-title":"Small cell carcinomas of the gastrointestinal tract: a review","volume":"22","author":"Brenner","year":"2004","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b71-0731729","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/1097-0142(19900201)65:3<422::AID-CNCR2820650308>3.0.CO;2-Y","article-title":"Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas","volume":"65","author":"Van der Gaast","year":"1990","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b72-0731729","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.04.8595","article-title":"Randomized phase III trial comparing irinotecan\/cisplatin with etoposide\/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer","volume":"24","author":"Hanna","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b73-0731729","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","article-title":"Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database","volume":"24","author":"Govindan","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b74-0731729","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1200\/JCO.2005.05.0575","article-title":"Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study","volume":"24","author":"Hainsworth","year":"2006","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b75-0731729","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg","year":"2010","journal-title":"Pancreas"},{"key":"key\n\t\t\t\t2019041103111539900_b76-0731729","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1200\/JCO.2004.04.024","article-title":"Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic neuroendocrine carcinomas","volume":"22","author":"Kouvaraki","year":"2004","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b77-0731729","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00280-006-0306-6","article-title":"Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?","volume":"59","author":"Bajetta","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019041103111539900_b78-0731729","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key\n\t\t\t\t2019041103111539900_b79-0731729","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2011.40.3147","article-title":"Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors","volume":"30","author":"Chan","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b80-0731729","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b81-0731729","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers; the Pancreas Center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"key\n\t\t\t\t2019041103111539900_b82-0731729","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","article-title":"Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors","volume":"8","author":"Casanovas","year":"2005","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t2019041103111539900_b83-0731729","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1200\/JCO.2008.21.5988","article-title":"Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway","volume":"28","author":"Missiaglia","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b84-0731729","first-page":"671","article-title":"Current development of mTOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nature Rev"},{"key":"key\n\t\t\t\t2019041103111539900_b85-0731729","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103111539900_b86-0731729","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041103111539900_b87-0731729","unstructured":"ClinicalTrials.gov. Everolimus plus best supportive care vs placebo plus best supportive care in the treatment of patients with advanced neuroendocrine tumors (GI or lung origin) (RADIANT-4). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01524783?term=NCT01524783&rank=1 (accessed 2015 Sep 7)."},{"key":"key\n\t\t\t\t2019041103111539900_b88-0731729","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1056\/NEJMc0806740","article-title":"Glycemic control in patients with insulinoma treated with everolimus","volume":"360","author":"Kulke","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103111539900_b89-0731729","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccr.2010.10.031","article-title":"AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity","volume":"19","author":"Chandarlapaty","year":"2011","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t2019041103111539900_b90-0731729","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1210\/jc.2011-2088","article-title":"Clinical review: current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy","volume":"97","author":"Bousquet","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041103111539900_b91-0731729","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103111539900_b92-0731729","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2013.470","article-title":"Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours","volume":"109","author":"Ahn","year":"2013","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b93-0731729","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumors: a multicenter, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b94-0731729","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2019041103111539900_b95-0731729","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdl144","article-title":"Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?","volume":"18","author":"Fazio","year":"2007","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b96-0731729","first-page":"690","article-title":"Oral administration of anti-neoplastic agents: the challenges for healthcare professionals","volume":"20","author":"Tadic","year":"2015","journal-title":"J BUON"},{"key":"key\n\t\t\t\t2019041103111539900_b97-0731729","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/ecc.12124","article-title":"Adherence to oral antineoplastic agents by cancer patients: definition and literature review","volume":"23","author":"Bassan","year":"2014","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"suppl 3","key":"key\n\t\t\t\t2019041103111539900_b98-0731729","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: oral chemotherapy","volume":"6","author":"Weingart","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"key\n\t\t\t\t2019041103111539900_b99-0731729","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JOP.2010.000068","article-title":"Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel","volume":"7","author":"Goodin","year":"2011","journal-title":"J Oncol Practice"},{"key":"key\n\t\t\t\t2019041103111539900_b100-0731729","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b101-0731729","first-page":"21","article-title":"Pulmonary toxicity of the rapamycin analog class of mTOR inhibitors","volume":"8","author":"Hudes","year":"2010","journal-title":"Kidney Cancer J"},{"key":"key\n\t\t\t\t2019041103111539900_b102-0731729","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mds115","article-title":"Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma","volume":"23","author":"Albiges","year":"2012","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b103-0731729","volume-title":"Afinitor (everolimus) prescribing information","year":"2009"},{"key":"key\n\t\t\t\t2019041103111539900_b104-0731729","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b105-0731729","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3816\/CGC.2009.n.002","article-title":"Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and nonrenal cell carcinoma: a meta-analysis","volume":"7","author":"Chu","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b106-0731729","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b107-0731729","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"key\n\t\t\t\t2019041103111539900_b108-0731729","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041103111539900_b109-0731729","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2009.4","article-title":"Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy","volume":"6","year":"2009","journal-title":"Nature Rev Clin Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b110-0731729","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041103111539900_b111-0731729","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t2019041103111539900_b112-0731729","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041103111539900_b113-0731729","first-page":"e61","article-title":"The effect of hand-foot skin reaction associated with multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"key\n\t\t\t\t2019041103111539900_b114-0731729","first-page":"319","article-title":"A review of cutaneous toxicities from targeted therapies in the treatment of colorectal cancers","volume":"4","author":"Urban","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"key\n\t\t\t\t2019041103111539900_b115-0731729","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","article-title":"Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"161","author":"Lee","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/21\/1729\/28334487\/ajhp1729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T21:03:28Z","timestamp":1601154208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/21\/1729\/5101771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,1]]},"references-count":115,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016,11,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp150373","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,11,1]]},"published":{"date-parts":[[2016,11,1]]}}}